Analysts are divided when it comes to Johnson & Johnson (NYSE:JNJ) stock. The medical device company experienced its share of ups and downs this year. It is currently one of many companies attempting to defend itself against ongoing opioid lawsuits. In August, an Oklahoma judge found Johnson & Johnson guilty of deceptive marketing practices and fined the company $572 million. The company allegedly marketed its opioid products as non-addictive, in spite of repeated warnings from the FDA.
The question for investors is, how important is this verdict and what will the ongoing lawsuit mean for JNJ stock? Here are three things you need to know about the opioid lawsuits. JNJ has been around for more than 130 years and is the largest healthcare company in the world. The company actively participates in nearly every aspect of the healthcare industry. That includes making consumer products, selling medical equipment, and making and distributing pharmaceuticals. So JNJ is a company that’s built to last. The opioid lawsuits will cause short-term problems for the company. JNJ stock has remained relatively flat over the last year and is up 2.4% in 2019. But the company should persevere in spite of its challenges.
Source: InvestorPlace
Related Articles:
- Why Dividend Growth Stocks Are Evil
- 4 Higher-Yielding Financial Services Stocks With Rising Dividends
- 5 Higher Yield Dividend Growth Stocks
- Successful Investors Take The Emotion Out
- 5 Under-Valued Dividend Growth Stocks
________________________________________________________________
Subscribe to:
Post Comments (Atom)
Popular Posts Last 30 Days
-
Here's an eye-opening statistic: older Americans are more afraid of running out of money than of death itself. And unfortunately, even r...
-
Today, we’ll look at three high-yield dividend stocks that have earned a ‘perfect 10’ from the Smart Score. For investors seeking a clear fo...
-
How do you assess risk? Different investors have different approaches, and when a Black Swan event topples the market, risk assessment becom...
-
Master limited partnerships (MLPs) have fallen out of favor with investors in recent years, thanks to a combination of continued turbulence ...
-
Many companies have been suspending their dividends during the COVID-19 crisis, and in many cases it is understandable. In times of economic...
-
While near-term fluctuations in the stock market can be unpredictable, dividends are one of the few reliable sources of market returns. Stoc...
-
With the price of oil rebounding, I wanted to find five cheap energy stocks that have solid dividend yields. In other words, the dividends a...
-
AbbVie (NASDAQ:ABBV) is in the midst of a transition. AbbVie began life about a decade ago when it was spun off from health care and medical...
-
3M Company (NYSE:MMM) is growing its FCF very well, and as a result, MMM stock is likely to move up at least 44% over the next or so. Right ...
-
This article deals with a sensitive subject - prisons, more precisely, US prisons. Regardless of which side of the argument one takes, sadly...
0 comments
Post a Comment
Post a Comment
Note: Only a member of this blog may post a comment.